Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Regulatory News (ZTF)

Share Price Information for Zotefoams (ZTF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 425.00
Bid: 425.00
Ask: 434.00
Change: 14.00 (3.41%)
Spread: 9.00 (2.118%)
Open: 411.00
High: 429.00
Low: 411.00
Prev. Close: 411.00
ZTF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

7 Nov 2023 07:00

RNS Number : 3591S
Zotefoams PLC
07 November 2023
 

Zotefoams plc

("Zotefoams" or "Group")

 

Trading Update

"Delivering on strategy - profit in line with market expectations"

 

7 November 2023 - Zotefoams, a world leader in cellular materials technology, today provides a trading update for the nine months ended 30 September 2023 ("year to date") and in respect of its financial year ending 31 December 2023.

Notwithstanding the challenging economic backdrop, the Group has continued to deliver a resilient performance, with year-to-date sales at a similar level to the comparative period of 2022, benefiting from a modest currency tailwind.

As anticipated, third quarter sales were lower year on year, reflecting subdued demand in most Polyolefin Foams markets, together with lower economic activity in China and an inventory adjustment in the supply chain to Nike. Against this backdrop, the Group continues to take effective pricing, cost and capacity management actions, which have enabled the business to remain agile and respond quickly to the volatility in demand dynamics.

The Group has also continued to invest in the development of ReZorce® recyclable barrier packaging technology and, following the signing of a joint development agreement, has made further progress against the milestones set, in advance of commercial trials scheduled for early 2024.

Full year expectation

The Group has good visibility of confirmed orders for the remainder of the year and expects to deliver revenue for 2023 at a similar level to 2022, albeit with an improved product mix.

Across our two foams business units, profitability for 2023 will see the positive benefit from an increasing proportion of sales from the HPP division, as well as the effect of strong pricing and operational efficiencies within Polyolefin Foams. Together with more favourable raw material and energy prices, this is expected to drive improved overall profitability, with margins significantly higher than the previous year.

In our MEL business unit, costs will increase as we further invest in ReZorce and address some legacy issues in the licensing and equipment business. The MEL business unit is now predominantly focused on the development of the ReZorce recyclable barrier packaging solution for beverage cartons. 

The Board is confident in the Group's ability to carry positive momentum through the remainder of the year. Based on its current sales forecasts and foreign exchange rates, and subject to there being no material disruption to the business, it expects adjusted profit before tax to be in line with current market expectations*.

 

Commenting on the update David Stirling, Group CEO of Zotefoams, said: 

"The Group is delivering on its strategy to drive efficiencies and generate an enhanced sales mix in its foams business units, and we anticipate a strong final quarter to the year and good underlying growth in profitability in this part of the Group, despite lower economic activity and destocking in many markets recently.

"We are also delivering on our commitment to develop recyclable beverage cartons. Investment in the high-risk, high-reward ReZorce technology is tracking in line with management expectations ahead of market trials and represents a significant proportion of Group costs, which are evaluated continuously in the context of the wider Group performance and the very significant opportunity represented by its target markets.

"These are two very different businesses with different organisational and operational requirements, which we are delivering to a high standard."

 

* Current Zotefoams-compiled consensus expectations for adjusted profit before income tax and separately disclosed items, for the year ending 31 December 2022, is £12.5m.

 

 - Ends -

 

Enquiries:

 

Zotefoams plc

+44 (0) 208 664 1600

David Stirling, Group CEO

Gary McGrath, Group CFO

 

 

IFC Advisory

 

+44 (0) 203 934 6630

Graham Herring

Tim Metcalfe

Zach Cohen

 

 

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular materials technology delivering optimal material solutions for the benefit of society. Utilising a variety of unique manufacturing processes, including environmentally friendly nitrogen expansion for lightweight AZOTE® polyolefin and ZOTEK® high-performance foams, Zotefoams sells to diverse markets worldwide. Zotefoams uses its own cellular materials to manufacture T-FIT® advanced insulation for demanding industrial markets. Zotefoams also owns and licenses patented microcellular foam technology to reduce plastic use in extrusion applications and for ReZorce® mono-material recyclable barrier packaging.

Zotefoams is headquartered in Croydon, UK, with additional manufacturing sites in Kentucky, USA and Brzeg, Poland (foam manufacture), Oklahoma, USA (foam products manufacture and conversion), Massachusetts, USA (MuCell Extrusion) and Jiangsu Province, China (T-FIT).

AZOTE®, ZOTEK®, ReZorce® and T-FIT® are registered trademarks of Zotefoams plc.

www.zotefoams.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUPGWUGUPWGUW
Date   Source Headline
12th Jul 201710:19 amRNSDirector/PDMR Shareholding
3rd Jul 20174:35 pmRNSPrice Monitoring Extension
13th Jun 20177:00 amRNSDirector/PDMR Shareholding
5th Jun 20172:14 pmRNSDirector/PDMR Shareholding
1st Jun 20174:30 pmRNSDirector/PDMR Shareholding
31st May 20177:00 amRNSDirector/PDMR Shareholding
17th May 20177:00 amRNSTrading Update
12th May 201711:16 amRNSDirector/PDMR Shareholding
12th Apr 20173:34 pmRNSAnnual Report and Accounts and Notice of 2017 AGM
12th Apr 20173:24 pmRNSDirector/PDMR Shareholding
12th Apr 20171:55 pmRNSHolding(s) in Company
10th Apr 20174:02 pmRNSDirector/PDMR Shareholding
6th Apr 20172:27 pmRNSHolding(s) in Company
6th Apr 20172:25 pmRNSHolding(s) in Company
28th Mar 201711:36 amRNSDirector/PDMR Shareholding
27th Mar 201710:16 amRNSHolding(s) in Company
24th Mar 20173:33 pmRNSHolding(s) in Company
23rd Mar 201710:11 amRNSHolding(s) in Company
22nd Mar 20173:28 pmRNSHolding(s) in Company
14th Mar 20175:28 pmRNSDirector/PDMR Shareholding
14th Mar 20177:00 amRNSFinal Results
9th Mar 20177:00 amRNSCoveris using MuCell® technology
15th Feb 201710:46 amRNSDirector/PDMR Shareholding
10th Feb 20177:00 amRNSHolding(s) in Company
1st Feb 20176:27 pmRNSHolding(s) in Company
12th Jan 20179:36 amRNSDirector/PDMR Shareholding
11th Jan 201710:33 amRNSHolding(s) in Company
10th Jan 20175:34 pmRNSHolding(s) in Company
9th Jan 20177:00 amRNSTrading Update
6th Jan 20177:00 amRNSAppointment of Joint Broker
6th Jan 20177:00 amRNSAcquires full ownership of its joint venture
22nd Dec 20164:35 pmRNSPrice Monitoring Extension
13th Dec 20161:58 pmRNSDirector/PDMR Shareholding
24th Nov 20167:00 amRNSHolding(s) in Company
15th Nov 201612:40 pmRNSDirector/PDMR Shareholding
14th Nov 201610:30 amRNSDirector Declaration
28th Oct 20167:00 amRNSThird Quarter Trading Update
25th Oct 20164:40 pmRNSSecond Price Monitoring Extn
25th Oct 20164:35 pmRNSPrice Monitoring Extension
24th Oct 201612:07 pmRNSSecond Price Monitoring Extn
24th Oct 201612:02 pmRNSPrice Monitoring Extension
20th Oct 20164:40 pmRNSSecond Price Monitoring Extn
20th Oct 20164:35 pmRNSPrice Monitoring Extension
19th Oct 20163:43 pmRNSHolding(s) in Company
18th Oct 201611:56 amRNSDirector/PDMR Shareholding
14th Oct 20164:35 pmRNSPrice Monitoring Extension
13th Oct 20164:35 pmRNSPrice Monitoring Extension
12th Oct 20165:56 pmRNSDirector/PDMR Shareholding
5th Oct 20164:29 pmRNSHolding(s) in Company
14th Sep 201611:16 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.